- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 31/542 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
Patent holdings for IPC class A61K 31/542
Total number of patents in this class: 433
10-year publication summary
43
|
44
|
39
|
30
|
24
|
32
|
40
|
23
|
29
|
13
|
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
Eisai R&D Management Co., Ltd. | 1233 |
17 |
Eli Lilly and Company | 3814 |
16 |
Shionogi & Co., Ltd. | 867 |
11 |
Sentiss Pharma Private Limited | 25 |
10 |
F. Hoffmann-La Roche AG | 7926 |
9 |
Erasca, Inc. | 85 |
9 |
Pfizer Inc. | 3367 |
8 |
Genentech, Inc. | 3961 |
7 |
Takeda Pharmaceutical Company Limited | 2704 |
7 |
Newave Pharmaceutical Inc. | 69 |
7 |
Novartis AG | 10904 |
5 |
Hoffmann-La Roche Inc. | 3379 |
5 |
Janssen Pharmaceutica N.V. | 3423 |
5 |
Wockhardt Limited | 227 |
5 |
Glaxosmithkline Intellectual Property Development Limited | 753 |
4 |
Alcon, Inc. | 5394 |
4 |
Rutgers, The State University of New Jersey | 1876 |
4 |
Santen Pharmaceutical Co., Ltd. | 604 |
4 |
Graybug Vision, Inc. | 21 |
4 |
Bristol-myers Squibb Company | 4892 |
3 |
Other owners | 289 |